Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tonix Pharmaceuticals

51.35
-8.2300-13.81%
Volume:2.78M
Turnover:137.37M
Market Cap:450.13M
PE:-0.86
High:53.50
Open:51.55
Low:45.22
Close:59.58
52wk High:130.00
52wk Low:6.76
Shares:8.77M
Float Shares:8.76M
Volume Ratio:2.70
T/O Rate:31.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-59.6633
EPS(LYR):-176.5980
ROE:-77.51%
ROA:-39.97%
PB:2.68
PE(LYR):-0.29

Loading ...

Stock Track | Tonix Pharmaceuticals Soars 7.28% Pre-market Despite Mixed Q2 Results, Fueled by Analyst Optimism and Strong YTD Performance

Stock Track
·
Yesterday

Stock Track | Tonix Pharmaceuticals Soars 7.28% Pre-market Despite Mixed Q2 Results, Boosted by Strong Overall Performance and Analyst Optimism

Stock Track
·
Yesterday

Stock Track | Tonix Pharmaceuticals Soars 5.74% Despite Mixed Q2 Results, Analyst Optimism Prevails

Stock Track
·
Yesterday

Tonix Pharmaceuticals Holding Corp reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Yesterday

Why Tonix Pharmaceuticals (TNXP) Stock Is Climbing This Week

Benzinga_recent_news
·
Aug 13

Noble Financial Sticks to Their Buy Rating for Tonix Pharma (TNXP)

TIPRANKS
·
Aug 13

Stock Track | Tonix Pharmaceuticals (TNXP) Soars 5.34% Pre-Market Ahead of Anticipated Earnings Report

Stock Track
·
Aug 13

Tonix Pharmaceuticals  reports Q2 net loss of  $28.3 mln

Reuters
·
Aug 12

Tonix Pharmaceuticals Q2 Basic EPS USD -3.86

THOMSON REUTERS
·
Aug 12

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

GlobeNewswire
·
Aug 12

Tonix Pharmaceuticals Unveils Presentation on TNX-1500 for Organ Transplant Rejection and Autoimmune Disorders

Reuters
·
Jul 30

Tonix Pharmaceuticals Reports Narrowed Net Loss for Q2 2025, Sales Slightly Decline

Reuters
·
Jul 26

Tonix Pharmaceuticals launches ‘Move Fibro Forward’ campaign

TIPRANKS
·
Jul 21

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

GlobeNewswire
·
Jul 10

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

GlobeNewswire
·
Jul 10

Tonix Pharmaceuticals Unveils New Investor Presentation Highlighting Development in Pain, Immunology, and Infectious Disease Solutions

Reuters
·
Jul 08

Tonix Pharmaceuticals to present on Mpox, smallpox vaccine candidate TNX-801

TIPRANKS
·
Jul 07

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

GlobeNewswire
·
Jul 07

Tonix Pharmaceuticals announces peer-reviewed publication of data on mTNX-1700

TIPRANKS
·
Jul 02

Tonix Pharmaceuticals announces inclusion in Russell 3000, Russell 2000 indexes

TIPRANKS
·
Jun 30